What one share of Humacyte holds
Humacyte, Inc. is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, and in the first quarter of 2025 commenced the United States commercial launch of our first FDA-approved product.
Humacyte’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.01 |
|---|---|
| Profit | −$0.50 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.50 |
| Cash and investments | $0.29 |
| Debt | $0.24 |
| Book value | $0.11 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$11.54 | $0.06 | −$9.69 | — | −$60.17 |
| 2021 | — | −$0.66 | $0.01 | −$2.04 | — | — |
| 2022 | — | −$0.12 | $0.01 | −$0.70 | — | $1.13 |
| 2023 | — | −$1.07 | $0.02 | −$0.73 | — | $0.13 |
| 2024 | $0.00 | −$1.26 | $0.01 | −$0.84 | — | −$0.41 |
| 2025 | $0.01 | −$0.26 | $0.01 | −$0.67 | — | $0.02 |
Common questions about Humacyte
How much does one share of Humacyte earn?
Over the last 12 months, Humacyte lost $0.50 for each share on $0.01 of sales.
Does Humacyte pay a dividend?
Humacyte didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Humacyte’s book value per share?
Humacyte’s book value is $0.11 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Humacyte have?
Each share of Humacyte has $0.29 of cash and investments and $0.24 of debt, as of June 30, 2026.
What is Humacyte’s free cash flow per share?
−$0.50 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Humacyte bought back shares?
Humacyte’s share count rose about 2643% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.